Kimberley Joanne Hatfield's picture

Kimberley Joanne Hatfield

Researcher, Researcher
  • E-mailKimberley.Hatfield@uib.no
  • Phone+47 55 97 30 37
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

The main research aim is to characterize metabolic phenotypes of human leukemia cells, and investigate how metabolic pathways may be implicated in the development of cancer cells`drug resistance.
Additional research interests include the contribution of the microenvironment in acute myeloid leukemia (AML); in particular how leukemia cells are influenced by stromal cells and chemokines, and how leukemia cells adapt to changes in oxygen levels and nutrient availability.

  • Show author(s) (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules.
  • Show author(s) (2021). Effects of the autophagyÔÇÉinhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. Journal of Personalized Medicine. 1-23.
  • Show author(s) (2020). The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia (AML) cells. International Journal of Molecular Sciences. 1-22.
  • Show author(s) (2020). Targeting cellular metabolism in acute myeloid leukemia and the role of patient heterogeneity. Cells. 1-26.
  • Show author(s) (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells.
  • Show author(s) (2019). Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.
  • Show author(s) (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Show author(s) (2018). The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. Cytotherapy. 740-754.
  • Show author(s) (2018). Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism. International Journal of Molecular Sciences. 1-18.
  • Show author(s) (2018). Patients with treatment-requiring chronic graft versus host disease after allogeneic stem cell transplantation have altered metabolic profiles due to the disease and immunosuppressive therapy: Potential implication for biomarkers. Frontiers in Immunology. 1-15.

More information in national current research information system (CRIStin)

Bergen Research Foundation funded project: Characterization of metabolic phenotypes and signaling pathways in acute myeloid leukemia and their role in anti-leukemia treatment.